Dolby Laboratories Inc (DLB) is Trading Lower on Unusual Volume for February 01

Equities Staff |

Dolby Laboratories Inc (DLB) experienced unusually high volume on Feb. 01, as the stock lost 0.72% to a closing price of $35.75. The stock saw 685,763 shares trade hands over the course of the day on 6,801 trades. Given that the stock’s average daily volume over the last month has been 417,671 shares a day, this represents a pretty substantial spike over the norm.

Dolby Laboratories Inc has a P/B ratio of 2. It also has a P/E ratio of 18.5. The stock has traded between $41.84 and $29.87 over the last 52-weeks, its 50-day SMA is now $33.43, and its 200-day SMA $35.39.

Dolby Laboratories Inc develops audio, video and voice technologies that transform entertainment and communications in mobile devices, at the cinema, at home and at work.

Headquartered in San Francisco, CA, Dolby Laboratories Inc has 1,867 employees and is currently under the leadership of CEO Kevin J. Yeaman.

For a complete fundamental analysis analysis of Dolby Laboratories Inc, check out’s Stock Valuation Analysis report for DLB. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…


The spark hit Jamie when he saw co-workers competing to lose weight. Instead of pizzas and subs, they were eating salads and jogging along the river. Some were sneakily leaving…